Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 16, 2015
Event: Entry into a Material Definitive Agreement for commercial cGMP manufacturing of CHS-1701 (pegfilgrastim biosimilar candidate) with KBI Biopharma, Inc.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or overall debt levels. It discloses specific contractual payment obligations related to the manufacturing agreement:
- Initial Manufacturing Campaign (2016): First installment of $7.8 million due in December 2015.
- Second Manufacturing Campaign (2017): Planned cost of $20.2 million.
Material Changes
The primary material change is the execution of a binding proposal on December 16, 2015, subject to a Master Services Agreement (MSA) dated July 30, 2014. This agreement commits the Company to purchasing production batches of its drug substance, including the initial campaign scheduled for 2016.
Outlook, Risks, and Unusual Items
- Management Commentary: The Company intends to submit a FOIA Confidential Treatment Request to redact certain portions of the Agreement.
- Contractual Flexibility: The Company retains the right to cancel production batches at any time with written notice, though this requires forfeiting a portion of commitments paid for capacity reservation.
- Future Filings: The full MSA and Proposal will be filed as exhibits to the Annual Report on Form 10-K for the fiscal year ended December 31, 2015.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can meet the $7.8 million payment due in December 2015.
- Review the upcoming Form 10-K for the full text of the Master Services Agreement and the binding proposal.
- Monitor the status of the FOIA Confidential Treatment Request to understand any redacted terms in the agreement.
- Assess the timeline for the 2016 manufacturing campaign and the 2017 campaign costing $20.2 million.